New drug applications approved by US FDA as of 16 - 30 November 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Supplementation with resistant starch for 12 weeks decreases the inflammatory marker tumour necrosis factor [TNF]-α and heart rate but does not significantly improve glycaemic control and other cardiovascular disease risk factors in prediabetic adults, suggests a study.
Use of the feminizing hormone therapy medroxyprogesterone acetate (MPA) results in minimal side effects, unchanged oestradiol levels and a decline in testosterone in a cohort of transwomen, a study has found.